Free Trial
NASDAQ:EVOK

Evoke Pharma Q2 2025 Earnings Report

Evoke Pharma logo
$4.57 -0.04 (-0.87%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$4.66 +0.09 (+1.86%)
As of 10/3/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.32
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$3.75 million
Expected Revenue
$3.80 million
Beat/Miss
Missed by -$44.00 thousand
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Evoke Pharma's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Evoke Pharma Earnings Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK) is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology. The company’s research efforts aim to extend the therapeutic potential of ghrelin receptor modulation into related indications, including postoperative ileus and chronic constipation. Evoke collaborates with academic and industry partners to optimize its pipeline and expand clinical development into new patient populations.

Founded in 2006 and headquartered in San Diego, California, Evoke Pharma completed its initial public offering on the Nasdaq under the ticker EVOK. The company serves patients across the United States and is exploring opportunities to establish international partnerships for broader market access. Evoke’s leadership team combines decades of experience in gastroenterology drug development, regulatory affairs and commercial strategy to advance its mission of improving quality of life for individuals with debilitating GI disorders.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat